Researcher
Peter Vandenberghe
- Disciplines:Genetics, Systems biology, Medical imaging and therapy, Molecular and cell biology, Other paramedical sciences
Affiliations
- Laboratory for Genetics of Malignant Disorders (Division)
Responsible
From1 Jan 2008 → Today - Department of Human Genetics (Department)
Member
From1 Apr 2009 → Today
Projects
1 - 10 of 19
- Establishing an evidence ecosystem for blood donation deferral criteria in men who have sex with menFrom9 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Map, Join and Drive European Activities for Advanced Therapy Medicinal Product Development and Implementation for Patient and Society BenefitFrom1 Jan 2024 → TodayFunding: Horizon Europe - Health
- PhD project to identify the immune signature after CAR T-cells treatment.From5 Nov 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- DIPITO: valorisation of deep immune profiling and novel immunotherapeutics for oncology.From1 Oct 2021 → TodayFunding: IOF - mandates
- In-depth investigation of patient immune signature after CD19 CAR T-cell therapyFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Integrated PK/PM Model-based Medication Dosing Assist App(lication) in KlinischWerkStation (KWS). Validation Studies of Tacrolimus in (Solid) Organ TransplantationFrom1 Jan 2021 → 31 Dec 2023Funding: IOF - technology validation in lab
- Mechanisms and Diagnosis of Mast Cell and Basophil Activation in Rare Hypersensitivity DisordersFrom1 Nov 2020 → TodayFunding: BOF - doctoral mandates
- Tracking Multiple Myeloma by low-pass sequencing of circulating cell free DNAFrom1 Mar 2019 → 1 Mar 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Circulating cell-free DNA as an alternative gateway to the genetic features of multiple myeloma and as a surrogate marker for disease burden in multiple myeloma.From1 Mar 2019 → 29 Feb 2024Funding: Nonprofit institution or equivalents
- Circulating cell-free DNA: a novel gateway to the genome of Hodgkin/Reed-Sternberg cells in Hodgkin Lymphoma?From1 Jan 2017 → 31 Dec 2020Funding: Foundations, funds and other with scientific goal
Publications
201 - 210 of 229
- FIP1L1-PDGFR alpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFR alpha T674I eosinophilic leukemia with single agent sorafenib(2009)
Authors: Lucienne Michaux, Peter Marynen, Jan Cools, Peter Vandenberghe
Pages: 845 - 851 - The t(14;20)(q32;q12): A Rare Cytogenetic Change in Multiple Myeloma (MM) Associated with Poor Outcome(2009)
Authors: Lucienne Michaux, Michel Delforge, Peter Vandenberghe
Pages: 901 - 904 - Chronic Myeloproliferative Neoplasms(2009)
Authors: Peter Vandenberghe, Lucienne Michaux
Pages: 209 - 232 - A large kindred with X-linked neutropenia with an I294T mutation of the Wiskott-Aldrich syndrome gene(2009)
Authors: Karolien Beel, Peter Vandenberghe
Pages: 120 - 126 - Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia(2009)
Authors: Carlos Graux, Annelies Simons, Lucienne Michaux, Peter Vandenberghe, Kim De Keersmaecker, Jan Cools
Pages: 125 - 133 - The T(14;20)(q32;q12) : A Rare Cytogenetic Change in Multiple Myeloma Associated with Poor Outcome.(2008)
Authors: Mmue-Christiane Vekemans, Heidi Lemmens, Chantal Doyen, Greet Bries, Hiide Demuynck, Pascal Pierre, Jan Lemmens, Peter Meeus, Michel Delforge, Deborah Bauwens, et al.
Pages: 939 - 939 - High-Dose Therapy in AL Amyloidosis: A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON)(2008)
Authors: PC Hazenberg Bouke, Sandra Croockewit, Ron van der Holt, Sonja Zweegman, Gerard Bos, Peter Vandenberghe, Pieter Sonneveld, Jan J Cornelissen, Edo Vellenga, Pierre W Wijermans, et al.
Pages: 67 - 67 - FIP1L1-PDGFR alpha D842V, a Novel Panresistant Mutant, Emerges after Treatment of FIP1L1-PDGFR alpha T674I Eosinophilic Leukemia with Single Agent Sorafenib(2008)
Authors: Peter Vandenberghe, Els Lierman, Lucienne Michaux, Pascal Pierre, Peter Marynen, Jan Cools
Pages: 1279 - 1279 - A myelodysplastic syndrome associated with a clonal GATA1 mutation(2008)
Authors: Kathleen Freson, Liesbeth De Waele, Chantal Thys, Marie-Christin Wittevrongel, Peter Vandenberghe, Rita De Vos, Paresh Vyas, Chris Van Geet
Pages: 451 - 452 - Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation(2008)
Authors: Barbara Dewaele, Bartosz Wasag, Jan Cools, Raf Sciot, Hans Prenen, Peter Vandenberghe, Agnieszka Wozniak, Patrick Schöffski, Peter Marynen, Maria Debiec-Rychter
Pages: 5749 - 5758